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Abstract
Objective Our aim was to estimate the prevalence-based
cost of illness imposed by nocturia (C2 nocturnal voids per
night) in Germany, Sweden, and the UK in an average year.
Methods Information obtained from a systematic review of
published literature and clinicians was used to construct an
algorithmdepicting themanagement of nocturia in these three
countries. This enabled an estimation of (1) annual levels of
healthcare resource use, (2) annual cost of healthcare resource
use, and (3) annual societal cost arising frompresenteeismand
absenteeism attributable to nocturia in each country.
Results In an average year, there are an estimated 12.5,
1.2, and 8.6 million patients C20 years of age with nocturia
in Germany, Sweden, and the UK, respectively. In an
average year in each country, respectively, these patients
were estimated to have 13.8, 1.4, and 10.0 million visits to
a family practitioner or specialist, *91,000, 9000, and
63,000 hospital admissions attributable to nocturia and
216,000, 19,000, and 130,000 subjects were estimated to
incur a fracture resulting from nocturia. The annual direct
cost of healthcare resource use attributable to managing
nocturia was estimated to be approximately €2.32 billion in
Germany, 5.11 billion kr (€0.54 billion) in Sweden, and
£1.35 billion (€1.77 billion) in the UK. The annual indirect
societal cost arising from both presenteeism and absen-
teeism was estimated to be approximately €20.76 billion in
Germany and 19.65 billion kr (€2.10 billion) in Sweden. In
addition, in the UK, the annual indirect cost due to
absenteeism was an estimated £4.32 billion (€5.64 billion).
Conclusions Nocturia appears to impose a substantial
socioeconomic burden in all three countries. Clinical and
economic benefits could accrue from an increased aware-
ness of the impact that nocturia imposes on patients, health
services, and society as a whole.
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Introduction
Individuals who awaken one or more times at night to void,
with each void being preceded and followed by sleep, are
considered to have nocturia [1]. However, those who
experience less than two voids per night are generally not
regarded as having clinically significant nocturia that
warrants diagnostic investigation and treatment. In con-
trast, people who experience two or more on a regular basis
are perceived to be experiencing a significantly bothersome
and clinically meaningful condition [2–4]. One conse-
quence of persistent nocturia is associated sleep fragmen-
tation, suggested by some to be more bothersome than
nocturnal voiding frequency per se [5]. Sleep fragmenta-
tion affects the most restorative stage of sleep (slow-wave
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sleep), which could have potentially deleterious impact on
daytime alertness, health, and well-being [6, 7].
While nocturia is usuallydefinedas awakening twoormore
times at night to void [2, 3], nocturnal polyuria is defined as
‘‘abnormally excessive urination during the night ([33 % of
urine production in 24 h in elderly individuals)’’ [8]. Patho-
physiologically, nocturia is frequently attributed to nocturnal
polyuria (nocturnal urine overproduction) [9], which is often
due to an altered endogenous production of arginine vaso-
pressin hormone. Nocturia can also be a consequence of a
range of causes, such as congestive heart failure, cirrhosis of
the liver, obstructive sleep apnea, nephrotic syndrome,
chronic renal disease, advanced age, side-effects from drugs
or low anatomical or functional bladder capacity (e.g., due to
bladder-wall fibrosis, overactive bladder syndrome, or benign
prostatic enlargement/bladder outlet obstruction) [1, 10].
The consequences of nocturia and associated poor sleep
include daytime fatigue, reduced quality of life (QoL), mood
disturbance, reduced productivity at work, poorer overall
health, and increased falls and fractures [11]. Notwithstanding,
nocturia is a relatively underreported condition, and the true
extent of the problem in the population is difficult to estimate.
Additionally, nocturia is often under- or misdiagnosed by the
treating physician [12, 13]. These factors may contribute to the
challenge of identifying patients for whom investigation and
corresponding treatment would be indicated.
Prevalence estimates in the published literature vary and
are affected by the population studied, the age range con-
sidered, and the definition of nocturia used. There have been
previous attempts to estimate the costs associated with
nocturia in Europe.However, they have generally focused on
individual components of healthcare or indirect societal
costs arising from lost productivity [14]. High-quality arti-
cles on the cost of illness associated with nocturia are gen-
erally lacking. Accordingly, the objectives of this studywere
to estimate the prevalence-based cost of illness imposed by
nocturia (C2 nocturnal voids per night) in Germany, Swe-
den, and theUK in an average year. Swedenwas selected as it
was considered to be representative of the Nordic countries.
Germany and the UK were selected as they were considered
to be representative of Western European countries. How-
ever, Germany’s healthcare systemallows patients to contact
specialists directly without prior referral from a family




This was a retrospective modelling study based on a sys-
tematic review of published literature and information
obtained from clinicians involved in managing nocturia in
Germany, Sweden, and the UK.
Literature review
A systematic literature review was performed by searching
EMBASE, PubMed, and Centre for Reviews and Dissem-
ination databases for relevant publications on nocturia (i.e.,
C2 nocturnal voids) published between January 2010 and
June 2015. The search terms focused on epidemiology,
clinical and health outcomes, management, resource use,
costs, and productivity. After applying various related
search terms in the databases, 2617 abstracts were
obtained. Of these, 2368 studies were excluded because of
duplication or lack of relevance. This generated 249 pub-
lications to review in full. A manual literature search was
subsequently conducted using the citations in the papers.
Published studies that reported epidemiological data for
only one gender were excluded from the analysis.
Due to the scarcity of country-specific studies, some data
from other European and non-European countries were also
extracted and analyzed. However, the included countries’
healthcare systems were similar to Germany, Sweden, and
the UK. Country-specific prevalence rates stratified by age
group and gender were only available for Sweden [15].
Mean prevalence rates were calculated for Germany and
the UK using data from Finland [16], Sweden [15], and the
USA [17], as they were the only available studies reporting
age- and gender-specific prevalence. No data were col-
lected for people aged C65 years in Sweden [15] and
C80 years in Finland [16]. Hence, the prevalence rates for
these age groups, stratified by gender, were extrapolated by
using the last three available data points from each study
(Tables 1 and 2). An annual incidence of 0.102 (i.e.,
number of new cases per population at risk in a given
12-month period), annual remission rate of 0.167 (i.e.,
proportion of patients in remission), and mortality data
[pooled Hazard ratio (HR) = 1.29] pertaining to nocturia
were obtained from published meta-analyses [18, 19].
The incidence of the main serious adverse consequences
of nocturia (i.e., falling and fracture) was generally
reported for the older patient population. A weighted mean
incidence for nocturia patients who fall during the night of
0.189 (i.e., proportion of patients who fall) was derived
using data on patients aged C70 years [20, 21]. The dis-
tribution of fall-related fractures attributable to nocturia
was applied to the incidence of fractures attributable to
nocturia of 0.041 (i.e., proportion of patients with a fall-
related fracture, both reported by Nakagawa et al. [22]) to
estimate the annual number of patients who experience
each fracture type in an average year. Based on these
calculations, the incidence of fall-related accidents without
subsequent fracture was estimated to be 0.148.
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Patient management
Due to the limited availability of published data, information
was obtained from surveys investigating the management of
nocturia patients in various countries. The number of noc-
turia-related consultations, hospitalizations, and over-the-
counter drugswas obtained from a cross-sectional real-world
survey involving 635 physicians who were actively manag-
ing urological patients in France, Germany, Spain, the UK,
and the USA [23, 24]. Additionally, data on drug treatments
were obtained from a nocturia market assessment survey in
Europe [25]. Estimates collected from these surveys are
summarized in Table 3.
The clinical authors involved in managing nocturia
patients in Germany, Sweden, and the UK estimated that
due to differences between healthcare systems in these
three countries, patients can have diverse treatment path-
ways. In Sweden and the UK, patients would initially see a
family practitioner who might refer them to a urologist, a
gynecologist, or a urogynecologist for further assessment.
However, in Germany, patients can seek medical help
directly from any physician without first seeing a family
practitioner.
The basic diagnostic tests for nocturia [e.g., frequency–
volume chart, symptom-score questionnaire, urinalysis,
urinary flow rate, measurement of postvoid residual (PVR)
urine] are the same in all three countries. However, ultra-
sound tests are generally not used to evaluate the cause of
nocturia in Sweden, and usually no additional fee specifi-
cally for this test would be charged in Germany. Therefore,
the cost of diagnostic ultrasound tests were excluded from
the base-case analysis in all three countries. The clinical
authors considered that once patients received a prescribed
drug, they would need to take it on an ongoing basis until
their symptoms disappeared. If a drug ceased to be effi-
cacious, patients would either need to switch to another
drug or take combined medication.
Nocturia patients can also suffer from other conditions
(e.g., diabetes, arterial hypertension, cardiac diseases,
depression, urinary tract infections) that usually precede
the onset of nocturia [26]. However, because of disturbed
nocturnal sleep, they also suffer from fatigue, loss of
attention and productivity during the day, falls, and bone
fracture.
Cost-of-illness models
Three country-specific cost-of-illness models comprising
12 one monthly cycles were constructed to estimate direct
and indirect costs attributable to nocturia (C2 nocturnal
voids) in Germany, Sweden, and the UK in an average year
(Fig. 1).
For each country, prevalence data (Tables 1 and 2) were
used to estimate the annual number of patients aged
20–89 years who experience C2 nocturnal voids. Using
published incidence rates, remission rates, and mortality
HRs, our analysis estimated the annual number of newly
diagnosed patients, patients who go into remission (i.e.,
experiencing \2 nocturnal voids) and discontinue treat-
ment, and patients who die as a consequence of their
nocturia (i.e., difference between the annual number of
nocturia patients who die and the annual number of deaths
in the general population using a mortality HR for nocturia
[19]; background mortality for causes other than nocturia
was not captured in the model). Hence, within the models,
existing patients enter the model in the first month. New
patients and patients in remission enter and leave the
patient pool each month during the year. Additionally,
deaths can occur in each month. The annual number of
patients who enter or leave the pool each month in the three
groups were distributed evenly throughout the year (by
dividing annual incidence, remission, and mortality data by
12). Therefore, the size of the open cohort of patients at any
one time depended on the number of newly diagnosed
patients, patients who started treatment in a previous per-
iod, patients who died, and patients who went into remis-
sion. Annual amounts of healthcare resource use and
corresponding costs were estimated separately for new
Table 1 Prevalence rates of nocturia in Sweden [15]







* Data in Asplund (2005) [15] was only collected for people
\65 years; it was assumed that the same rates were valid for people
between 65 and 69 years
** Estimated as described in the text
Table 2 Estimated mean prevalence rates of nocturia used for Ger-
many and the UK [15–17]
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patients and patients diagnosed with nocturia in previous
years. However, the relative risk (RR) of having a fall or
fracture was assumed to be the same for both newly
diagnosed and existing patients.
In the base-case analysis, all patients from previous
years were assumed to continue treatment for the year
unless they went into remission or died. However, newly
diagnosed patients were assumed to have to wait to see a
specialist physician in accordance with country-specific
average waiting times [27–29]. Moreover, patients gener-
ally received only lifestyle advice and a voiding diary to
complete at the first visit. Accordingly, it was assumed that
newly diagnosed patients would not start treatment until
their second visit to a clinician, which would take place
*1 month after the first appointment. This impacts on the
number of clinician visits and length of treatment
Table 3 Information obtained from the surveys
Information obtained Value Survey
Mean number of nocturia-related consultations in a year: overall 3.6 [23]
Mean number of nocturia-related consultations in a year: family practitioner 4 [23]
Mean number of nocturia-related consultations in a year: urologist 3.4 [23]
Percentage of patients hospitalized because of nocturia in a year 2.6 % [23]
Percentage of patients buying over-the-counter drugs in Germany 22 % [23]
Percentage of patients seeking medical help 34 % [25]
Percentage of patients seeing a urologist as a first point of contact 25 % [25]
Percentage of patients seeing a family practitioner as a first point of contact 60 % [25]
Percentage of patients seeing a gynecologist as a first point of contact 6 % [25]
Percentage of patients seeing other specialists as a first point of contact 9 % [25]
Percentage of patients ever consulted a urologist 47 % [25]
Percentage of patients ever consulted a family practitioner 67 % [25]
Percentage of patients ever consulted a gynecologist 11 % [25]
Percentage of patients seen by a urologist or a gynecologist receiving prescribed drugs 53 % [25]
Percentage of patients seen by a family practitioner receiving prescribed drugs 23 % [25]
Percentage of patients receiving anticholinergics from a urologist 40 % [25]
Percentage of patients receiving a-blockers from a urologist 40 % [25]
Percentage of patients receiving 5a-reductase inhibitors from a urologist 15 % [25]
Percentage of patients receiving antidiuretic hormone replacement from a urologist 10 % [25]
Percentage of patients receiving anticholinergics from a family practitioner 50 % [25]
Percentage of patients receiving a-blockers from a family practitioner 30 % [25]
Percentage of patients receiving 5a-reductase inhibitors from a family practitioner 15 % [25]
Percentage of patients receiving antidiuretic hormone replacement from a family practitioner 5 % [25]
Percentage of patients receiving anticholinergics from a gynecologist 100 % [25]
Percentage of patients receiving antidiuretic hormone replacement from a gynecologist 5 % [25]
Percentage of patients referred to another specialist by a urologist or a gynecologist 13 % [25]
Percentage of patients referred to another specialist by a family practitioner 36 % [25]
Enter the open cohort 
each monthly cycle 
Annual incidence: 0.102
Leave the open cohort each  
monthly cycle 
Annual remission rate: 0.167 
Annual rate of nocturia–related deaths: 0.007 
Fig. 1 Cost-of-illness algorithm depicting the movement of nocturia patients entering and leaving the open cohort in an average year
D. Weidlich et al.
123
experienced by newly diagnosed patients in the study year
in the models. The number of falls and fractures and
associated costs were estimated for both newly diagnosed
and existing patients C70 years of age.
Indirect societal costs arising from absenteeism (i.e.,
being absent from work) and presenteeism (i.e., attending
work when unwell, thus not working productively) were
estimated for both newly diagnosed and existing patients
aged between 20 and 64 years. Incremental values of
absenteeism and presenteeism were estimated by calcu-
lating differences between nocturia patients [23, 30] and
the general population [30–32] for each country. The costs
of absenteeism and presenteeism were derived using
national average monthly salaries [33] and the estimated
incremental number of months that patients of working age
are absent from work or do not work productively due to
nocturia.
Due to a lack of data, presenteeism in the UK could not
be estimated. Furthermore, based on findings from the
available sources [23, 30, 31], people with nocturia in
Germany and Sweden do not appear to be absent from
work more than the general population. Therefore, it was
assumed that there were no indirect costs arising from
absenteeism due to nocturia in these two countries.
Resource use and costs
Resource use was obtained from various sources: the two
abovementioned surveys [23, 25], the clinical authors, and
published literature [20–22]. Some data were not available;
thus, the following assumptions were made:
• If a patient was referred to a specialist, only one
additional specialist visit was assumed.
• Patients would initially visit their family practitioner in
Sweden and the UK.
• Patients who have a fall would visit an accident and
emergencydepartment; thosewith fractureswould require
some type of fracture-related procedure in a hospital.
Unit costs at 2014–2015 prices were obtained from
published sources (Table 4) and applied to the resource use
estimates in the models to estimate the total annual direct
cost of healthcare resource use and the annual indirect
societal cost arising from presenteeism and absenteeism
attributable to nocturia in the individual countries. If cost
data was only available from previous years, values were
uprated to 2014–2015 prices.
Sensitivity and scenario analyses
To assess whether any variable had a major impact on
total direct or indirect costs of nocturia, one-way
sensitivity analyses were performed on all model inputs.
Base-case values were decreased and increased by
25 %. Various scenarios were also assessed to estimate
the effect of increasing or decreasing the values of
groups of variables (e.g., unit costs of drugs, number of
visits in a year) and including the cost of an ultrasound
test in the diagnostic tests. In addition, the impact of
including the cost of treating depression, a condition
that is suggested to have a bidirectional association with
nocturia [34], was examined. In this scenario it was
assumed that 10.82 % of patients had depression (a
weighted mean estimated using Miyazato et al. (2014)
[35] and Tikkinen et al. (2010) [36]) and needed cor-
responding treatment. Probabilistic sensitivity analysis
was also undertaken to evaluate parameter uncertainty
within the models. This involved 10,000 iterations of
the models by simultaneously varying the different
inputs. To estimate random values of inputs, the stan-
dard error (SE) was assumed to be 10 % around the
mean values, and relevant distributions were assigned to
the deterministic values. Beta distribution was used for
probabilities, log-normal distribution for resource use
estimates, and time variables and gamma distribution
for costs enabling distributions of annual direct and
indirect costs to be estimated.
Results
Prevalence of nocturia
Using prevalence data shown in Tables 1 and 2, the annual
number of people aged C20 years experiencing two or
more nocturnal voids per night was estimated (Table 5).
Clinician visits
The estimated annual number of clinician visits
attributable to managing patients experiencing C2 noctur-
nal voids per night is summarized in Table 6. Family
practitioner visits account for more than half of all clinician
visits in all three countries, and visits to a urologist account
for another quarter.
Prescriptions
An estimated 11 % of all sufferers in each country received
prescribed drugs. Irrespective of country, 50 % of these
patients received an anticholinergic, 32 % an a-blocker,
13 % a 5a-reductase inhibitor, and 8 % desmopressin
(ADH replacement). Table 6 summarises the reimbursable
drugs that are prescribed for nocturia patients.
Annual direct and indirect costs attributable to nocturia in Germany, Sweden, the UK
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Falls and fractures
Twenty-two percent of falls among patients aged
C70 years were estimated to result in a fracture. Of
patients who had a fracture, it was estimated that 30 % had
an arm fracture, 40 % had a lower limb fracture, 20 % had
a lumber spine and pelvic fracture, and 10 % had a com-
bination of other fracture types [22]. Additionally, 1 % of
all patients were admitted into hospital (Table 6).
Annual direct healthcare cost of managing nocturia
The direct annual cost of healthcare resource use
attributable to managing nocturia was estimated to be
approximately €2.32 billion in Germany, 5.11 billion kr
(€0.54 billion) in Sweden, and £1.35 billion (€1.77 billion)
in the UK (Table 7). Falls and fractures were the primary
cost driver in Germany, accounting for 48 % of annual
costs. In Sweden and the UK, clinician visits were the pri-
mary cost driver accounting for 59–60 % of the annual cost.
Annual indirect societal cost attributable to nocturia
In Germany and Sweden, it was estimated that patients of
working age do not take time off work due to their nocturia
[23, 30, 31]. Instead, they were estimated to not work
productively for a total of*1 month in an average year. In
contrast, patients in the UK were estimated to be absent
from work for a total of 0.4 months in an average year.
However, no data were available to estimate their







Urologist 18.44 3886.00 99.00 UK [44], Germany [45], Sweden [46]
Family practitioner 16.51 1397.00 56.50 UK [47], Germany [45], Sweden [48]
Gynecologist 14.79 2489.00 135.00 UK [44], Germany [45], Sweden [46]
Other specialists 23.88 2933.00 133.00 UK [44], Germany [45], Sweden [46]
Diagnostic tests 0.00 854.00 1.00 UK [44], Sweden [49]
Drugs used per month
Anticholinergics 38.49 251.12 23.09 UK [50], Germany [51], Sweden [52]
a-Blockers 20.66 130.91 5.59 UK [50], Germany [51], Sweden [52]
5a-Reductase inhibitors 23.56 82.42 15.42 UK [50], Germany [51], Sweden [52]
Antidiuretic hormone replacement therapy 121.50 345.02 27.32 UK [50], Germany [53], Sweden [52]
Over-the-counter drugs 5.40 0.00 0.00 [23]
Other related treatments
Hospital bladder procedures 4982.97 35,424.94 1759.79 UK: [44], Germany [54, 55], Sweden [49]
Treatment after a fall 19.73 2323.50 135.00 UK [44], Germany [45], Sweden [49]
Hospital procedure to treat an arm fracture 4556.96 58,607.29 1939.83 UK [44], Germany [54, 55], Sweden [49]
Hospital procedure to treat a lower limb fracture 4037.71 66,273.80 1688.74 UK [44], Germany [54, 55], Sweden [49]
Hospital procedure to treat a lumbar spine and pelvic
fracture
8409.20 63,380.60 2262.82 UK [44], Germany [54, 55], Sweden [49]
Hospital procedure to treat any other minor fracture 3898.36 56,448.03 1767.40 UK [44], Germany [54, 55], Sweden [49]
Indirect costs
Average monthly gross salary 3042.83 31,468.08 2744.67 [33]
1 kr & €0.11, £1 & €1.31
Table 5 Annual number of
patients C20 years of age with
nocturia in Germany, Sweden,
and the UK
Germany Sweden UK
Annual number of new patients 6,678,852 750,936 4,976,168
Annual number of existing patients 5,781,168 462,289 3,652,994
Total annual number of patients 12,460,020 1,213,225 8,629,162
Annual number of patients going into remission 2,080,823 202,609 1,441,070
Annual number deaths due to nocturia 93,399 8657 57,075
D. Weidlich et al.
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productivity at work (Table 8). Accordingly, the annual
indirect societal cost arising from both presenteeism and
absenteeism was estimated to be approximately €20.76
billion in Germany and 19.65 billion kr (€2.10 billion) in
Sweden. In the UK, the annual indirect cost due to
absenteeism was an estimated £4.32 billion (€5.64 billion)
(Table 8).
Sensitivity and scenario analyses
The one-way sensitivity analyses indicated two inputs that
had the most significant impact on direct healthcare costs in
all three countries. Changing (1) the annual number of
nocturia patients and (2) the percentage of patients who
seek medical help by ±25 % increased and decreased
direct costs by 19–29 % and 13–19 %, respectively. In
scenarios (Table 9) in which the number or unit cost of all
types of visits were modified by ±25 %, direct healthcare
costs increased and decreased most considerably in Sweden
(by 15 % in both scenarios) and the UK (by 14–15 %) and
much less in Germany (by 3 % in both scenarios).
Including the cost of an ultrasound test within the cost of
diagnostic tests increased direct costs to a greater extent in
Sweden (by 12 %) and to a smaller extent in Germany (by
1 %) and the UK (by 5 %). In the scenario in which the
cost of depression was also taken into account, the cost per
Table 6 Annual amounts of healthcare resource use attributable to nocturia in Germany, Sweden, and the UK
Germany Sweden UK
Clinician visits
Annual number of visits to a family practitioner 7,722,803 (56 %) 811,774 (59 %) 5,826,666 (59 %)
Annual number of visits to a urologist 3,717,666 (27 %) 333,948 (24 %) 2,479,061 (25 %)
Annual number of visits to a gynecologist 934,985 (7 %) 84,298 (6 %) 624,562 (6 %)
Annual number of visits to other specialists 1,454,748 (11 %) 146,948 (11 %) 1,026,830 (10 %)
Total annual number of clinician visits 13,830,202 (100 %) 1,376,968 (100 %) 9,957,118 (100 %)
Prescribed drugs
Total number of patients receiving prescribed drugs in a year* 1,404,931 133,707 963,033
Annual number of patients taking anticholinergics 705,371 66,957 482,904
Annual number of patients taking a-blockers 449,415 42,863 308,382
Annual number of patients taking 5a-reductase inhibitors 187,608 17,915 128,810
Annual number of patients taking desmopressin (ADH replacement) 107,346 10,202 73,533
Hospital activity
Annual number of falls among patients aged C70 years 997,235 88,085 599,918
Annual number of fall-related fractures among patients aged C70 years 216,331 19,108 130,141
Annual number of hospital admissions 90,926 8857 63,038
Percentage of total number of visits in parentheses
ADH antidiuretic hormone
* Some patients can take a combination of drugs
Table 7 Total annual direct healthcare cost (at 2014–2015 prices) of managing nocturia in Germany, Sweden, and the UK
Total direct annual healthcare costs attributable to managing nocturia
Germany (€) Sweden (kr) UK (£)
Clinician visits 244,625,051 (11 %) 3,072,586,752 (60 %) 795,517,872 (59 %)
Prescribed drugs 472,403,515 (20 %) 194,126,227 (4 %) 137,443,084 (10 %)
Over-the-counter drugs 37,607,278 (2 %) 0 (0 %) 0 (0 %)
Diagnostic tests 0 (0 %) 180,073,118 (4 %) 1,398,160 (0 %)
Hospitalization 453,083,943 (20 %) 313,770,214 (6 %) 110,934,067 (8 %)
Falls and fractures 1,108,709,552 (48 %) 1,352,870,393 (26 %) 308,963,298 (23 %)
Total direct cost 2,316,429,339 (100 %) 5,113,426,704 (100 %) 1,354,256,481 (100 %)
Total direct cost per patient 185 4215 157
Total direct cost per capita 29 525 21
1 kr & €0.11, £1 & €1.31. Percentage of total cost in parentheses
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case in each of the three countries was obtained from a
European-wide study [37] in which the cost per case
included both direct and indirect costs of different brain
disorders. Hence, using these estimates might have resulted
in a double-counting of indirect costs. Consequently, the
total annual direct and indirect cost attributable to nocturia
would increase by approximately €11.51 billion in
Germany, 6.49 billion kr (€0.69 billion) in Sweden, and
£4.15 billion (€5.41 billion) in the UK if the cost of
depression was included in the analysis. Probabilistic sen-
sitivity analysis (10,000 iterations of the models) estimated
mean total annual direct healthcare costs of:
• €2.24 billion [95 % confidence interval (CI) €2.21–2.28
billion) in Germany
• 5.10 billion kr (95 % CI 4.98–5.14 billion) [€0.54
billion (95 % CI 0.53–0.55)] in Sweden
• £1.34 billion (95 % CI 1.32–1.36 billion) [€1.75 billion
(95 % CI 1.72–1.78)] in the UK.
Similarly, this analysis estimated mean total annual
indirect societal costs of:
• €20.80 billion (95 % CI 20.46–21.13 billion) in
Germany
• 19.50 billion kr (95 % CI 19.20–19.79 billion) [€2.08
billion (95 % CI 2.05–2.11)] in Sweden
• £4.33 billion (95 % CI 4.26–4.40 billion) [€5.65 billion
(95 % CI 5.56–5.75)] in the UK.
Discussion
This study estimated the economic burden that nocturia
imposes on healthcare systems and society as a whole in
three typically different European countries: Germany,
Sweden, and the UK. The total annual direct healthcare cost
of £1.4 billion attributable to managing nocturia in the UK is
comparable with the annual National Health Service (NHS)
cost of managing dementia (£1.5 billion at 2013–2014 pri-
ces) [38]. The total annual direct healthcare cost of €2.3
billion attributable to managing nocturia in Germany is
comparable with the total annual direct healthcare cost of
managing diseases of the thyroid gland and acute upper
respiratory tract infections (€2.3 billion and €2.2 billion at
2014–2015 prices respectively) in Germany [39]. The total
annual direct healthcare cost attributable to managing noc-
turia in Sweden (5.1 billion kr) is concordant with the total
annual direct healthcare cost of managing overactive bladder
syndrome (3.7 billion kr at 2014–2015 prices) in Sweden
[40]. Comparable costs for managing overactive bladder
syndrome in Germany and the UK were estimated to be €1.4
billion and £0.9 million, respectively [40].
The total annual direct healthcare cost of managing a
nocturia patient in Germany (€186 per patient) and the UK
[€205 (£157) per patient] were comparable. However, the
corresponding cost in Sweden [€449 (4215 kr) per patient]
was more than twofold greater that in the other two
countries. The reason appears to be the unit cost of clini-
cian visits and most hospital procedures in Sweden being
higher than in the other two countries (Table 3).
We were unable to stratify our findings according to
patient age. However, younger patients may experience
more troubled sleep and associated problems than older
patients [41]. Irrespective of whether sleep interruptions
are caused or exacerbated by nocturia, these may affect the
general state of health and well-being of sufferers. Fur-
thermore, the negative effects of nocturia may be particu-
larly difficult for younger patients because they are more
likely to have more active lifestyles and demanding work
schedules than older patients [42]. As proportionally more
younger than older adults are expected to be employed,
nocturia is seen as having a disruptive economic impact
that is disproportional to the prevalence of this condition
relative to that of older adults. Indeed, we estimated that
Table 8 Absenteeism and presenteeism due to nocturia and corresponding total annual indirect societal cost due to lost productivity (at
2014–2015 prices) in Germany, Sweden, and the UK
Germany Sweden UK
Percentage of patients of working age (i.e., 20–64 years) 49 % 48 % 51 %
Number of months not working productively due to nocturia (per patient) 1.13 1.06 N/A
Number of months absent from work due to nocturia (per patient) 0.00 0.00 0.36
Total annual indirect costs due to presenteeism €20,759,295,433 19,647,399,994 kr N/A
Total annual indirect costs due to absenteeism €0 0 kr £4,316,264,416
Total indirect cost €20,759,295,433 19,647,399,994 kr £4,316,264,416*
Total indirect cost per patient €1666 16,194 kr £500
Total indirect cost per capita €256 2016 kr £67
1 kr & €0.11, £1 & €1.31
* This only includes indirect costs due to absenteeism
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the total annual indirect societal cost attributable to noc-
turia ranges from €20.8 billion in Germany to 19.7 billion
kr in Sweden to £4.3 billion in the UK. Notwithstanding,
others have reported that older patients with moderate to
severe nocturia (C3 nocturnal voids) incur significantly
higher total medical costs, greater number of hospitaliza-
tion days, higher inpatient medical costs, and higher out-
patient medical costs than younger patients [43].
Furthermore, our analysis suggests there is no absenteeism
from work as a direct result of nocturia in Germany and
Sweden. By way of comparison, this would not appear to
be the case for patients with overactive bladder syndrome
in these countries [40]. Hence, the annual indirect societal
cost attributable to overactive bladder syndrome has been
estimated to be €441.3 million in Germany, 726.4 million
kr (€77.38 million) in Sweden, and £199.0 million
(€259.84 million) in the UK at 2014–2015 prices [40].
This analysis has several limitations: it is based on a
systematic review of published literature and clinician
experiences. Accordingly, the models were constructed by
combining data from numerous, and in many instances
non-European, countries with assumptions derived from
the clinical authors. Additionally, patient-level data were
not available for the study. As the clinical basis of the
models was diverse studies, patient populations may not be
identical in all of them. Consequently, the modelled patient
populations may not necessarily reflect patients who are
managed in clinical practice in Germany, Sweden, and the
UK, and the observed clinical outcomes may not neces-
sarily reflect those observed from patient cohorts in clinical
practice.
The models were based on many assumptions pertaining
to prevalence, incidence, mortality, and remission rates.
The effect of all these limitations and the uncertainty sur-
rounding the results underwent sensitivity analyses. Nev-
ertheless, the results may be subject to unknown
confounders.
The published literature describes various comorbidities
that might be associated with nocturia. However, there is
no clear evidence on the causal relationships between these
comorbidities and nocturia [26]. Consequently, it was
decided to exclude the cost of managing those
Table 9 Total annual direct and indirect costs estimated with one-way sensitivity and scenario analyses in Germany, Sweden, and the UK













Base-case result €2.32 €20.76 5.11 kr 19.65 kr £1.35 £4.32





Change the number of patients seeking medical help by ±25 % €2.01–2.62 No effect 4.17–6.05
kr
No effect £1.09–1.62 No effect
Change the annual number of clinician visits by ±25 % €2.25–2.38 No effect 4.33–5.90
kr
No effect £1.16–1.55 No effect
Change the percentage of patients receiving drug prescriptions by
±25 %
€2.20–2.43 No effect 5.06–5.16
kr
No effect £1.32–1.39 No effect
Change the percentage of hospitalized patients by ±25 % €2.20–2.43 No effect 5.03–5.19
kr
No effect £1.33–1.38 No effect
Change the percentage of patients with a fracture by ±25 % €2.04–2.59 No effect 4.82–5.41
kr
No effect £1.29–1.42 No effect
Change the unit costs of clinician visits by ±25 % €2.26–2.38 No effect 4.35–5.88
kr
No effect £1.16–1.55 No effect
Change the costs of drugs by ±25 % €2.19–2.44 No effect 5.06–5.16
kr
No effect £1.32–1.39 No effect
Change the unit costs of hospitalization and nocturia-related
procedures by ±25 %
€1.93–2.71 No effect 4.70–5.53
kr
No effect £1.25–1.46 No effect
Include the cost of an ultrasound test as within the diagnostic tests €2.35 No effect 5.74 kr No effect £1.43 No effect
0–2 months in a year of not working productively due to nocturia No effect €0–36.85 No effect 0–37.00 kr N/A N/A
0–1 month in a year of being absent from work due to nocturia N/A N/A N/A N/A No effect £0–12.15
40–60 % of patients are of working age (20–64 years) No effect €17.09–25.63 No effect 16.22–24.33
kr
No effect £3.37–5.05
1 kr & €0.11, £1 & €1.31
* This only includes indirect costs due to absenteeism
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comorbidities where there was any ambiguity regarding
their relationship with nocturia. Nevertheless, the analysis
can be updated once additional evidence becomes avail-
able. Notwithstanding, a scenario analysis estimated the
impact of including the cost of depression, which was
reported in a systematic review [34] to have a bidirectional
association with nocturia.
Healthcare resource use was not collected prospectively
but was estimated retrospectively from surveys and the
clinical authors. Consequently, resource use for the ‘‘av-
erage clinician’’ may not be the same as for clinicians who
participated in this study and may not be indicative of the
entire populations of Germany, Sweden, or UK. The
models incorporated resource use values for an ‘‘average
patient’’ and did not take into account disease stage and
patient characteristics such as age, gender, and comor-
bidities. In addition, the possibility of changing treatments
(i.e., varying the number of different drug prescriptions)
within a year was excluded from the analysis due to scarce
applicable data; similarly, resource use and corresponding
costs of managing patients in remission were excluded.
The study was performed from the perspective of the
health service in each country and society as a whole.
However, direct costs incurred by patients (including any
co-payments), families, and/or caregivers were excluded
(except for over-the-counter medication in Germany) due
to the paucity of data. Inclusion of all missing costs (e.g.,
patient co-payments, cost of managing patients in remis-
sion) may affect study results and warrant further investi-
gation. Therefore, generalizing results of this study to other
healthcare systems would be challenging. Although
healthcare systems in these three countries differ from each
other, they could be viewed as being representative of
similar types of healthcare structures. Hence, study results
for Germany could be generalized to other Western Euro-
pean countries where patients can visit a specialist without
a prior referral from a family practitioner. Conversely,
study results for the UK could be indicative of other
Western European countries with a primary-care gate-
keeper system. Furthermore, results for Sweden could be
representative of other Nordic countries.
In conclusion, nocturia appears to impose a substantial
socioeconomic burden in Germany, Sweden, and the UK.
Clinical and economic benefits could accrue from an
increased awareness of the impact that nocturia imposes on
patients, health services, and society as a whole.
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